Phase 3
Completed N=221
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Ocular Inflammation Associated With Blepharaconjunctivitis
Source: ClinicalTrials.gov NCT00576251 ↗
Enrolled (actual)
221
Serious AEs
0.0%
Results posted
Jan 2010
Primary outcomePrimary: Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4) — 100.0; 94.4 Percent of patients
Summary
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4) |
100.0; 94.4 | — |
Eligibility Criteria
Inclusion Criteria
- Ocular inflammation associated with blepharaconjunctivitis
Exclusion Criteria
- ocular allergy
- ocular disorders that would preclude safe administration of test article
Data sourced from ClinicalTrials.gov (NCT00576251). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.